{
    "clinical_study": {
        "@rank": "106088", 
        "brief_summary": {
            "textblock": "To evaluate the efficacy of WR 6026 once daily in the treatment of mild PCP. To evaluate the\n      safety and tolerance of WR 6026. To assess the correlation between plasma WR 6026\n      concentrations and outcome/toxicity."
        }, 
        "brief_title": "A Study of WR 6026 in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients", 
        "completion_date": {
            "#text": "July 1998", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "detailed_description": {
            "textblock": "All patients will receive an initial loading dose of WR 6026, followed the next morning and\n      each morning thereafter by 1 of 2 lower doses of WR 6026 taken in a fasting state for 3\n      weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Any medications not listed as excluded will be permitted on study.\n\n        [ AS PER AMENDMENT 4/11/97:PCP prophylaxis is permitted if initiated after the Day 21\n        evaluation has been completed.]\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  Documented PCP.\n\n          -  On a room air ABG, the PO2 value greater than or equal to 70 mm Hg and the (A-a) DO2\n             less than 35 mm Hg.\n\n          -  Signed informed consent from parent or legal guardian for those patients less than 18\n             years of age.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Known hypersensitivity to quinolines.\n\n          -  If patient is unwilling or unable to discontinue other medications with anti-PCP\n             activity during the treatment period of this study.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Any patient unwilling or unable to discontinue other medications with anti-PCP\n             activity during the treatment period of this study (e.g., TMP/SMX, sulfonamides,\n             dapsone, pentamidine, trimetrexate, atovaquone, clindamycin, azithromycin,\n             pyrimethamine, primaquine).\n\n          -  Methemoglobinemia-producing agents (dapsone, primaquine, sulfonamides, chloroquine,\n             nitrofurantoin, nitrates and nitrites).\n\n        Patients with the following prior conditions or symptoms are excluded:\n\n          -  History of G6PD deficiency, hemoglobin M abnormality, or NAD methemoglobin reductase\n             deficiency.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  More than 24 hours receipt of anti-PCP treatment for the current episode of PCP.\n             Receipt of prior PCP prophylaxis is permitted, as long as it is discontinued at study\n             entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "45", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000863", 
            "org_study_id": "ACTG 314", 
            "secondary_id": "11289"
        }, 
        "intervention": {
            "intervention_name": "Sitamaquine", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Pneumonia, Pneumocystis carinii", 
            "Administration, Oral", 
            "WR 6026"
        ], 
        "lastchanged_date": "March 30, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Alabama Therapeutics CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii", 
                        "zip": "96816"
                    }, 
                    "name": "Queens Med. Ctr."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii", 
                        "zip": "96816"
                    }, 
                    "name": "Univ. of Hawaii at Manoa, Leahi Hosp."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60640"
                    }, 
                    "name": "Weiss Memorial Hosp."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana Univ. School of Medicine, Wishard Memorial"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Methodist Hosp. of Indiana"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana Univ. School of Medicine, Infectious Disease Research Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14215"
                    }, 
                    "name": "SUNY - Buffalo, Erie County Medical Ctr."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "NY Univ. HIV/AIDS CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "Univ. of Cincinnati CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "The Ohio State Univ. AIDS CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study of WR 6026 for Pneumocystis Carinii Pneumonia in People With HIV Infection", 
        "overall_official": [
            {
                "last_name": "Dohn M", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Petty B", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Black J", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Frame P", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "citation": "Petty B, Black J, Hendrix C, Bassiakos Y, Feinberg J, Hafner R. Escalating multiple-dose safety and tolerance of WR 6026 in HIV-infected subjects. Int Conf AIDS. 1993 Jun 6-11;9(1):498 (abstract no PO-B29-2180)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000863"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2012"
    }, 
    "geocoordinates": {
        "Alabama Therapeutics CRS": "33.521 -86.802", 
        "Indiana Univ. School of Medicine, Infectious Disease Research Clinic": "39.769 -86.158", 
        "Indiana Univ. School of Medicine, Wishard Memorial": "39.769 -86.158", 
        "Methodist Hosp. of Indiana": "39.769 -86.158", 
        "NY Univ. HIV/AIDS CRS": "40.714 -74.006", 
        "Northwestern University CRS": "41.878 -87.63", 
        "Queens Med. Ctr.": "21.307 -157.858", 
        "SUNY - Buffalo, Erie County Medical Ctr.": "42.886 -78.878", 
        "The Ohio State Univ. AIDS CRS": "39.961 -82.999", 
        "Univ. of Cincinnati CRS": "39.103 -84.512", 
        "Univ. of Hawaii at Manoa, Leahi Hosp.": "21.307 -157.858", 
        "Weiss Memorial Hosp.": "41.878 -87.63"
    }
}